Daily Express Subscriber
Sign in to your account.

Kuala Lumpur: The ImmuSAFE Covid+ biochip test, jointly developed between Malaysia Automotive, Robotics and IoT Institute (MARii), Sengenics and the Institute for Medical Research (IMR), will be used as one of the tests to verify the efficacy of the various vaccines used in Malaysia.

This is in line with the goal to achieve herd immunity from Covid-19 under the National Covid-19 Immunisation Plan, said MARii in a statement, Wednesday.

“The Ministry of Health (MOH) has announced that the immune response tests related to Covid-19 vaccines will be done using the ImmuSAFE biochip technology. ImmuSAFE is the world’s first lab-based, multi-antigen and multi-domain Covid-19 serology test (examination of blood serum) comprising of nine functionally validated domains or regions of the Nucleocapsid (N) and Spike (S) protein of SARS-CoV-2 expressed using Sengenics’ KREX protein folding technology,” it said.

According to the statement, the test was fully quantitative, enabling high-throughput screening of Covid-19 samples for diagnosis of current or prior infection, as well as for quantitation and localisation of antibody binding, thereby providing a means to identify antibody correlates of ongoing protection and development of durable immunity against future SARS-CoV-2 infection.

MARii said the ImmuSAFE test allowed quantitative testing of the prevalence of protective antibodies against Covid-19, developed by the body's immune system, either through vaccination or natural development from an infection.

“This means that ImmuSAFE provides a measurable verification method to verify the effectiveness of any immunisation roll out, regardless of the type of vaccine,” it added.